人 CD160 抗体对
01AB01645
CD160 molecule (CD160) is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein expressed on NK cells, cytotoxic CD8+ T cells, and intestinal intraepithelial lymphocytes. It contains a single Ig-like V-type domain and binds broadly to classical and non-classical MHC class I molecules, as well as the TNF receptor family member HVEM. CD160 functions as a dual-purpose immune modulator, delivering co-inhibitory signals to CD4+ T cells while providing activating signals to NK cells via the PI3K-AKT-mTOR pathway to enhance cytokine production and cytotoxicity. Clinically, CD160 acts as an immune checkpoint; its dysregulation is linked to impaired immune function in cancer and HIV infection. It is currently being investigated as a therapeutic target for cancer immunotherapy and the management of pathological neoangiogenesis.
| 规格 | 起售价 |
|---|---|
| 登录后可查看 | |
技术参数
- 靶点基因名
- CD160
- 基因别名
- BY55
- 蛋白别名
- CD160 molecule; CD160
- UniProt
- O95971
- 物种
- Human
产品详情
- 靶点名称
- CD160
- 蛋白名称
- CD160 molecule
- 蛋白别名
- CD160 antigen; Natural killer cell receptor BY55; CD antigen CD160) [Cleaved into: CD160 antigen; soluble form]
- 靶点基因名
- CD160
- 基因别名
- BY55
- UniProt
- O95971
- 来源物种
- Homo sapiens (Human)
- 物种反应性
- Human
背景介绍
CD160 molecule (CD160) is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein expressed on NK cells, cytotoxic CD8+ T cells, and intestinal intraepithelial lymphocytes. It contains a single Ig-like V-type domain and binds broadly to classical and non-classical MHC class I molecules, as well as the TNF receptor family member HVEM. CD160 functions as a dual-purpose immune modulator, delivering co-inhibitory signals to CD4+ T cells while providing activating signals to NK cells via the PI3K-AKT-mTOR pathway to enhance cytokine production and cytotoxicity. Clinically, CD160 acts as an immune checkpoint; its dysregulation is linked to impaired immune function in cancer and HIV infection. It is currently being investigated as a therapeutic target for cancer immunotherapy and the management of pathological neoangiogenesis.